Arbutus Biopharma Corp
Statements
Cash Flow
Arbutus Biopharma Corp (ABUS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -6.0 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15 | -15 | -18 | -5.1 | -16 | -10 | -20 | -18 | -13 | -17 | -17 | -18 | -23 | -13 | -15 | -8.8 | -12 | -15 | -18 | -14 | -16 | -20 | 21 | -20 | -19 | -17 | -27 | -20 | -22 | -17 | -19 | -15 | -21 | -10 | -13 | -16 | -5.8 | -4.7 | -8.1 | -6.0 | -25 | |
| 0.3 | 0.3 | 0.3 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 4.5 | 4.7 | 4.5 | 5.1 | 4.0 | 1.5 | 1.0 | 2.7 | 1.8 | 0.8 | 1.5 | 3.8 | 1.5 | 0.0 | 1.4 | 1.6 | 1.7 | 1.4 | 1.6 | 1.7 | 1.6 | 1.4 | 1.7 | 2.1 | 1.7 | 1.7 | 2.1 | 3.0 | 2.5 | 1.7 | 2.0 | 3.2 | 2.2 | 1.6 | 3.6 | 0.9 | 1.3 | 1.3 | 1.4 | 1.6 | 5.5 | |
| 189 | 201 | 5.2 | 4.2 | 2.8 | 18 | 0.7 | -21 | 9.4 | 2.5 | 6.3 | 7.2 | 57 | -12 | 0.9 | 1.1 | 3.7 | -2.5 | 0.8 | 2.3 | 0.6 | -0.5 | 0.6 | 1.9 | -0.4 | 1.0 | 1.2 | 1.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.9 | 2.1 | -4.4 | 8.5 | -7.5 | 6.5 | -3.8 | 0.0 | 1.3 | -1.8 | -0.1 | -2.0 | 0.1 | -0.2 | -4.0 | 2.6 | 1.3 | 0.5 | -3.7 | 2.6 | 1.0 | 1.0 | 35 | -7.6 | -1.4 | 3.5 | -12 | -4.0 | -3.4 | 1.5 | -2.9 | 2.8 | -2.5 | -0.2 | 5.3 | -18 | 1.2 | 1.8 | -178 | -2.2 | -177 | |
| 0.2 | 2.6 | 3.4 | 3.1 | 0.5 | 0.2 | 0.2 | 0.4 | 0.2 | 0.2 | 0.0 | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 | 0.1 | 0.6 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.9 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 8.1 | 6.0 | 14 | |
| -0.9 | 0.7 | 23 | -1.4 | 5.3 | 0.7 | -76 | 15 | 24 | 45 | 61 | 10.0 | 16 | -59 | -2.4 | 23 | 14 | -50 | 18 | -39 | 16 | -8.1 | -60 | -14 | -14 | 13 | 17 | 1.4 | 10 | 22 | 12 | 9.8 | -12 | 13 | 11 | 16 | -10 | -1.4 | 2.2 | -1.7 | -11 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 | 2.6 | 10 | 2.7 | 2.8 | 2.8 | 11 | 3.0 | 3.0 | 9.0 | 12 | 3.2 | 3.3 | 12 | 12 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 0.0 | 0.4 | 0.0 | 0.1 | 49 | 66 | 0.7 | 0.4 | 0.1 | 2.5 | 2.5 | 5.0 | 14 | 12 | 5.0 | 49 | 20 | 27 | 4.3 | 47 | 59 | 11 | 0.1 | 9.1 | 11 | 0.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 12 | – | -12 | -12 | -12 | -12 | – | – | -12 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 12 | 0.4 | 0.0 | 0.1 | 49 | 54 | 0.7 | 0.4 | 0.1 | 2.5 | 2.5 | 19 | 14 | 12 | 5.0 | 49 | 20 | 27 | 4.3 | 47 | 59 | 11 | 0.1 | 9.1 | 11 | 20 | 4.7 | 1.7 | 3.8 | 24 | 24 | 1.8 | 1.4 | 2.8 | 0.5 | 0.8 | 1.6 | 12 | 3.1 | 17 | |
| -16 | -3.2 | 6.4 | -5.6 | -9.0 | 39 | -42 | -2.3 | 12 | 15 | 47 | -5.1 | 11 | -58 | -5.4 | 19 | 51 | -45 | 27 | -48 | 47 | 31 | -28 | -34 | -23 | 6.8 | 9.8 | -13 | -9.7 | 8.8 | 17 | 20 | -31 | 4.5 | 0.7 | 0.3 | -15 | -4.4 | 5.7 | -4.5 | -18 | |
| -15 | -17 | -21 | -8.2 | -16 | -11 | -20 | -18 | -13 | -17 | -17 | -18 | -24 | -13 | -15 | -8.9 | -12 | -15 | -18 | -15 | -16 | -20 | 21 | -21 | -19 | -17 | -27 | -20 | -22 | -17 | -19 | -15 | -21 | -10 | -13 | -16 | -5.8 | -4.7 | -8.1 | -6.0 | -25 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.